Acute challenge with apomorphine and levodopa in parkinsonism

Research output: Contribution to journalArticle

Abstract

Although the recognition of a parkinsonian syndrome may be immediate, the clinical diagnosis of idiopathic Parkinson's disease (PD) remains difficult, due to the lack of specific biological markers. Other parkinsonian syndromes may present with similar clinical features and clinical diagnostic errors Alberto Albanese have been demonstrated in pathological series [1]. Approximately 75% of patients seen at movement disorder clinics exhibit the typical features of PD [2]; they may respond favorably to dopaminergic treatment and are likely to receive a clinical diagnosis of PD. Still, the diagnosis of PD is confirmed pathologically in only about 75% of these patients [1]. Response to antiparkinsonian medication is closely related to the diagnosis. PD always responds (often dramatically) to treatment with levodopa or dopamine agonists. Thus, a lack or loss of response to levodopa is considered incompatible with a diagnosis of PD [1, 3] and has been used as a criterion for the diagnosis of multiple-system atrophy (MSA) [4]. However, parkinsonian syndromes other than PD (e.g., drug-induced parkinsonism, MSA, autosomal recessive juvenile parkinsonism) may also improve significantly with dopaminergic drugs [3, 5-8].

Original languageEnglish
Pages (from-to)60-63
Number of pages4
JournalFocus on Parkinson's Disease
Volume13
Issue number3
Publication statusPublished - 2001

Fingerprint

Apomorphine
Parkinsonian Disorders
Levodopa
Parkinson Disease
Multiple System Atrophy
Antiparkinson Agents
Dopamine Agents
Dopamine Agonists
Movement Disorders
Diagnostic Errors
Biomarkers
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Acute challenge with apomorphine and levodopa in parkinsonism. / Albanese, A.

In: Focus on Parkinson's Disease, Vol. 13, No. 3, 2001, p. 60-63.

Research output: Contribution to journalArticle

@article{3db30156b71f43fc8bbf5598374a71a8,
title = "Acute challenge with apomorphine and levodopa in parkinsonism",
abstract = "Although the recognition of a parkinsonian syndrome may be immediate, the clinical diagnosis of idiopathic Parkinson's disease (PD) remains difficult, due to the lack of specific biological markers. Other parkinsonian syndromes may present with similar clinical features and clinical diagnostic errors Alberto Albanese have been demonstrated in pathological series [1]. Approximately 75{\%} of patients seen at movement disorder clinics exhibit the typical features of PD [2]; they may respond favorably to dopaminergic treatment and are likely to receive a clinical diagnosis of PD. Still, the diagnosis of PD is confirmed pathologically in only about 75{\%} of these patients [1]. Response to antiparkinsonian medication is closely related to the diagnosis. PD always responds (often dramatically) to treatment with levodopa or dopamine agonists. Thus, a lack or loss of response to levodopa is considered incompatible with a diagnosis of PD [1, 3] and has been used as a criterion for the diagnosis of multiple-system atrophy (MSA) [4]. However, parkinsonian syndromes other than PD (e.g., drug-induced parkinsonism, MSA, autosomal recessive juvenile parkinsonism) may also improve significantly with dopaminergic drugs [3, 5-8].",
author = "A. Albanese",
year = "2001",
language = "English",
volume = "13",
pages = "60--63",
journal = "Focus on Parkinson's Disease",
issn = "0924-2015",
publisher = "Excerpta Medica",
number = "3",

}

TY - JOUR

T1 - Acute challenge with apomorphine and levodopa in parkinsonism

AU - Albanese, A.

PY - 2001

Y1 - 2001

N2 - Although the recognition of a parkinsonian syndrome may be immediate, the clinical diagnosis of idiopathic Parkinson's disease (PD) remains difficult, due to the lack of specific biological markers. Other parkinsonian syndromes may present with similar clinical features and clinical diagnostic errors Alberto Albanese have been demonstrated in pathological series [1]. Approximately 75% of patients seen at movement disorder clinics exhibit the typical features of PD [2]; they may respond favorably to dopaminergic treatment and are likely to receive a clinical diagnosis of PD. Still, the diagnosis of PD is confirmed pathologically in only about 75% of these patients [1]. Response to antiparkinsonian medication is closely related to the diagnosis. PD always responds (often dramatically) to treatment with levodopa or dopamine agonists. Thus, a lack or loss of response to levodopa is considered incompatible with a diagnosis of PD [1, 3] and has been used as a criterion for the diagnosis of multiple-system atrophy (MSA) [4]. However, parkinsonian syndromes other than PD (e.g., drug-induced parkinsonism, MSA, autosomal recessive juvenile parkinsonism) may also improve significantly with dopaminergic drugs [3, 5-8].

AB - Although the recognition of a parkinsonian syndrome may be immediate, the clinical diagnosis of idiopathic Parkinson's disease (PD) remains difficult, due to the lack of specific biological markers. Other parkinsonian syndromes may present with similar clinical features and clinical diagnostic errors Alberto Albanese have been demonstrated in pathological series [1]. Approximately 75% of patients seen at movement disorder clinics exhibit the typical features of PD [2]; they may respond favorably to dopaminergic treatment and are likely to receive a clinical diagnosis of PD. Still, the diagnosis of PD is confirmed pathologically in only about 75% of these patients [1]. Response to antiparkinsonian medication is closely related to the diagnosis. PD always responds (often dramatically) to treatment with levodopa or dopamine agonists. Thus, a lack or loss of response to levodopa is considered incompatible with a diagnosis of PD [1, 3] and has been used as a criterion for the diagnosis of multiple-system atrophy (MSA) [4]. However, parkinsonian syndromes other than PD (e.g., drug-induced parkinsonism, MSA, autosomal recessive juvenile parkinsonism) may also improve significantly with dopaminergic drugs [3, 5-8].

UR - http://www.scopus.com/inward/record.url?scp=0034779372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034779372&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0034779372

VL - 13

SP - 60

EP - 63

JO - Focus on Parkinson's Disease

JF - Focus on Parkinson's Disease

SN - 0924-2015

IS - 3

ER -